Cancer cells that resist treatment often exploit fundamental immune surveillance mechanisms, and new research reveals how acute myeloid leukemia (AML) hijacks a critical protein interaction to evade destruction. This discovery could transform treatment approaches for one of the most aggressive blood cancers, particularly for patients harboring high-risk genetic mutations.
The investigation demonstrates that FLT3-ITD mutations—present in roughly 30% of AML cases—directly interact with CMTM6 protein through their transmembrane domains. This interaction stabilizes PD-L1 expression on cancer cell surfaces, creating a molecular shield that prevents T-cells from recognizing and eliminating malignant cells. Importantly, this protein stabilization occurs without increasing RNA transcription, indicating a post-translational mechanism that had previously escaped detection.
Mouse transplantation experiments revealed striking survival benefits when CMTM6 was genetically removed from FLT3-mutated leukemia cells. Animals receiving CMTM6-deficient cancer cells showed dramatically reduced tumor burden and enhanced T-cell activity, with decreased expression of exhaustion markers that typically render immune cells ineffective. The therapeutic potential became apparent when combining anti-PD-L1 antibodies with tandutinib, a FLT3 inhibitor, which significantly improved outcomes compared to single-agent therapy.
This represents a paradigm shift in understanding AML immune evasion. While FLT3 inhibitors have shown modest clinical success as monotherapy, this research suggests their true potential lies in combination with immunotherapy. The direct protein-protein interaction mechanism offers a compelling rationale for dual targeting strategies, potentially explaining why some FLT3-mutated patients fail current treatments despite initial responses.